
Acadia Pharmaceuticals (ACAD) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
| Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
|---|---|---|---|---|
| Q3 | Nov 4, 2026 | $0.31 | $0.18 | 72.2 % |
| Q2 | Aug 4, 2026 | $0.18 | $0.04 | 350.0 % |
| Q1 | May 6, 2026 | $0.02 | $0.07 | -71.4 % |
| Q4 | Feb 25, 2026 | $0.14 | $0.13 | 7.69 % |
Quarterly Revenue (Billions)
| Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
|---|---|---|---|---|
| Q3 | Nov 4, 2026 | $342.29M | $333.02M | 2.79 % |
| Q2 | Aug 4, 2026 | $307.96M | $295.22M | 4.31 % |
| Q1 | May 6, 2026 | $268.06M | $280.65M | -4.48 % |
| Q4 | Feb 25, 2026 | $283.99M | $292.52M | -2.92 % |
Acadia Pharmaceuticals (ACAD) publicó su última previsión de noviembre 4, 2026 para fiscal year 2026. La compañía estimó ingresos en un rango de $1.26B - $1.29B para el período.
En comparación con la previsión anterior, Acadia Pharmaceuticals mantenido redujo su previsión de ingresos desde un rango anterior de $1.24B - $1.3B.
Acadia Pharmaceuticals ha emitido 15 actualizaciones de orientación entre el febrero 27, 2023 y el noviembre 4, 2026. During this period, the company raised its outlook 5 times and lowered it 2 times, providing investors with insight into management's evolving expectations.
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.18 | $0.04 | $0.07 | $0.13 |
| Actual | $0.31 | $0.18 | $0.02 | $0.14 |
| Surprise | +72.2% | +350.0% | -71.4% | +7.69% |
| Revenue | ||||
| Estimate | $333.0M | $295.2M | $280.6M | $292.5M |
| Actual | $342.3M | $308.0M | $268.1M | $284.0M |
| Surprise | +2.79% | +4.31% | -4.48% | -2.92% |
| Metric | Q4 '26E | Q1 '27E | Q2 '27E | Q3 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $0.27 | $0.23 | $0.21 | $0.22 |
| Revenue | ||||
| Consensus | $363.3M | $347.8M | — | — |